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Abstract: Atherosclerosis is a chronic inflammatory disorder characterized by immune cell activation, inflammation 
driven plaque formation and subsequent destabilization. In other disorders of an inflammatory nature, the chronic inflam-
matory state per se has been linked to acceleration of the atherosclerotic process which is underlined by an increased inci-
dence of cardiovascular disease (CVD) in disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis 
(RA) and antiphopholipid (Hughes) syndrome (APS). SLE is an autoimmune disease that may affect any organ. Premature 
coronary heart disease has emerged as a major cause of morbidity and mortality in SLE. In addition to mortality, cardio-
vascular morbidity is also markedly increased in these patients, compared with the general population. The increased car-
diovascular risk can be explained only partially by an increased prevalence of classical risk factors for cardiovascular dis-
ease; it also appears to be related to inflammation. Inflammation is increasingly being considered central to the pathogene-
sis of atherosclerosis and an important risk factor for vascular disease. Recent epidemiologic and pathogenesis studies 
have suggested a great deal in common between the pathogenesis of prototypic autoimmune disease such as SLE and that 
of atherosclerosis. 
We will review traditional risk factors for CVD in SLE. We will also discuss the role of inflammation in atherosclerosis, 
as well as possible treatment strategies in these patients.  
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INTRODUCTION 
  Systemic lupus erythematosus (SLE) is an autoimmune 
disease that primarily affects young women. Cardiac in-
volvement in patients with SLE can involve all components 
of the heart, including the pericardium, conduction system, 
myocardium, valves, and coronary arteries [1, 2]. Coronary 
artery disease (CAD) in SLE was described much later than 
the other cardiovascular manifestations. The clinical mani-
festations of CAD in SLE can result from several patho-
physiologic mechanisms, including atherosclerosis, arteritis, 
thrombosis, embolization, spasm, and abnormal coronary 
flow [2].  
  The striking clinical characteristic of most patients with 
SLE who have a myocardial infarction is their young age. 
This demographic characteristic suggests that patients with 
SLE are at increased risk of myocardial infarction and that 
reports of myocardial infarction in patients with SLE do not 
simply represent chance occurrences. Fatal myocardial in-
farction has been reported to be 3 times higher in patients 
with SLE than in age- and gender -matched control subjects 
[1, 4]. Recent case- control series have confirmed that the 
risk of myocardial infarction in patients with SLE is in-
creased between 9- and 50-fold over that in the general 
population [1-3]. It has been increasingly recognized that 
patients with SLE have a high cardiovascular mortality. Lu-
pus is now considered to be an independent risk factor for 
the development of atherosclerosis. Viewing atherosclerosis 
asaninflammatory disease, this association becomes stronger 
and better understood. 
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  Epidemiological observations have linked inflammation 
with the cardiovascular events [1, 2]. Clinical epidemiologi-
cal observations strongly suggest that, together with classical 
conventional risk factors, other mechanisms (non-conven-
tional/disease-specific factors) promote accelerated athero-
sclerosis in diseases like SLE and other rheumatic diseases 
[3-7]. The excess risk observed in autoimmune disease ap-
pears to be driven by systemic inflammation, directly or indi-
rectly through its damaging effects on the vasculature; and 
thus the concept of inflammation as a cardiovascular risk 
factor [3, 6, 7]. 
  We will review the association of atherosclerosis and 
inflammation in general population, with emphasize in the 
role of endothelial dysfunction and autoantibodies. We fur-
ther will review the presence of traditional and nontraditional 
risk factors in SLE patients.  
ATHEROSCLEROSIS AND INFLAMMATION 
  Inflammation and atherosclerosis have been linked for 
decades, although the underlying mechanism and the anti-
gens causing immune activation are not totally elucidated [7-
10]. Activated monocytes, macrophages and T cells and cy-
tokines have an important role in atherogenisis. C reactive 
protein (CRP) is considered an indentpendent risk factor for 
CVD. In addition, autoantigens and autoantibodies have also 
important roll in atherogenisis in general population [7, 10].  
Endothelium and Atherosclerosis 
  The endothelium is a single layer of cells that lines the 
luminal surface of blood vessels [8-10]. It is strategically 
situated to act as a direct interface between the components 
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local blood vessel functions, including vascular tone, cell 
adhesiveness, coagulation, inflammation, and permeability. 
The endothelium is able to produce and react to several po-
tent, locally active mediators and it recruits inflammatory 
cells to sites of tissue damage [9-10]. Endothelial dysfunc-
tion is a key event in atherogenesis and appears before the 
histopatholical evidence of atherosclerotic lesion [7, 11]. 
Chronically raised levels of inflammatory mediators may 
drive the inflammation that subsequently contributes to en-
dothelial damage [12]. Chronic ED and vascular inflamma-
tion may be induced both by conventional risk factors and 
systemic inflammation are important mechanisms in athero-
genesis [11, 12]. 
  During the initial stages of atherosclerosis, monocytes 
and T cells are recruited to the vessel wall across an intact 
endothelium. In order to pass the endothelium, adhesion 
molecules are necessary to be expressed in the inner layer of 
the endothelium. Several adhesion molecules may promote 
the adherence of monocytes, including intercellular adhesion 
molecule 1[ICAM-1], vascular cell adhesion molecule 1 
[VCAM-1] and selectins) [7, 10]. These adhesion molecules 
are surface proteins and their expression are mainly regu-
lated by transcription [10, 13] and induced by pro-inflam-
matory mediators, such as tumour necrosis factor alpha 
(TNF-), interleukin-1 (IL-1), C-reactive protein (CRP) and 
CD40/CD40 ligand interaction [7, 10-12, 14-16].  
Inflamation and Atherosclerosis in General Population 
  Systemic inflammation may be regarded as accelerating 
the atherosclerotic process, in especially CRP has been asso-
ciated with CVD risk in the general population. CRP, an 
acute phase protein commonly used to measure inflammation 
in autoimmune diseases, has also an important role in 
atherogenisis of normal population, both in the early initia-
tion of atherosclerotic lesions and in the conversion of stable 
to unstable plaques. The biological effect of CRP on athero-
sclerosis development seems to encompass a complex net-
work of interactions with the cells involved in plaque growth 
and development. CRP has also proatherogenic properties by 
being capable of activating the complement system, inducing 
endothelial production of monocyte chemotactic protein-
1(MCP-1) and secretion of endothelin-1 (ET-1) and interleu-
kin 6 (IL-6), up regulating adhesion molecules (ICAM-1, 
VCAM-1, selectins), mediating macrophage uptake of LDL 
and stimulating monocyte production of tissue factor [7, 17-
19]. 
  Epidemiological and clinical studies have shown strong 
and consistent relationships between markers of inflamma-
tion and risk of future CVD events. Therefore CRP levels 
may be considered an independent risk factor for myocardial 
infarction and stroke in men with and without other tradi-
tional risk factors [17]. Prospective epidemiological studies 
have shown that increased levels of CRP, predicts coronary 
events in healthy individuals and in patients with stable and 
or unstable angina [20].  
  This strong predictive value of CRP may be explained by 
its long-term stability during storage, its long-life, its lack of 
diurnal variation, and its lack of age and sex dependency [7, 
20].  
Autoantigens and Atherosclerosis 
  Evidence from studies of human disease supports the 
involvement of autoantigens in atherosclerosis. Numerous 
autoantigens and their respective autoantibodies are involved 
in the pathogenesis of atherosclerosis [21, 22]. A cellular 
immune response specifically directed against heat-shock 
proteins (HSPs), oxidized low-density lipoprotein (oxLDL), 
and _2-glycoprotein-I (_2GPI) has been reported, suggesting 
a direct involvement of these molecules in atherosclerosis 
[23, 24]. There are probably many more such specific cell 
lines reacting with specific antigens that can modulate athe-
rosclerosis by either aggravating or decreasing its extent 
(proatherogenic or antiatherogenic). 
Heat-Shock Proteins (HSPs) 
  The human HSPs are a group of proteins that are in-
volved in maintaining the folding of several cell components. 
They are expressed at high levels on endothelial cells in re-
sponse to stress factors in order to maintain the viability of 
targeted cells and may therefore become a target for auto-
immunity [21, 25]. Stress factors include hypertension, 
smoking, lipoproteins, oxidants and many others. There are 
clinical, subclinical, and experimental data that anti-HSP60/ 
65 has a proatherogenic role. Patients with high levels of 
anti-HSP65 were found to be at increased risk of subsequent 
cardiovascular events and cardiovascular mortality [26, 27]. 
Furthermore, patients with sonographic evidence of carotid 
atherosclerotic lesions had significantly elevated levels of 
anti-HSP65 when compared to controls [22, 28]. 
Anti-Oxidized Low-Density Lipoprotein (oxLDL) 
  LDL is constituted by molecules of phospholipids, 
triglycerides, and cholesterol, and accumulates in macro-
phages. During early atherogenesis, LDL become trapped in 
the subendothelial space and is subsequently oxidized [22, 
29]. This oxLDL is thought to be responsible for triggering 
inflammatory responses in macrophages and vascular wall 
cells. It increases the adhesive properties of endothelial cells 
and induces the activation of monocytes and T cells [22, 30-
32]. OxLDL is the type of LDL that is more likely to un-
dergo uptake by macrophages, which turn into the foam cells 
characterizing atherosclerotic lesions. Anti-oxLDL antibod-
ies are present in patients with atherosclerosis, independently 
of its etiology [33, 34]. Anti-oxLDL autoantibodies seems to 
be able to discriminate patients with peripheral vascular dis-
ease and control subjects and there is also a tendency for 
higher autoantibody levels in patients with more extensive 
atherosclerosis [33].
Antiphospholipid Antibodies 
  Antiphospholipid antibodies are a heterogeneous group 
of autoantibodies, including, anticardiolipin antibody (aCL) 
and lupus anticoagulant (LA), generally directed to phos-
pholipid binding proteins; in this regard, 2GPI represents 
the major antigenic target [21]. 2GPI can be found in human 
atherosclerotic lesions obtained from carotid endarterecto-
mies, it is abundantly expressed within the subendothelial 
regions and the intimal-medial border of human atheroscle-
rotic plaques, and it colocalizes with CD4_ lymphocytes [22, 
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atherosclerosis, suggesting that _2GPI is a target autoantigen 
in atherosclerosis. 
SLE AND ATHEROSCLEROSIS 
  SLE is an autoimmune disease with a variety of clinical 
manifestations that occurs predominantly young women 
[22]. In the general population atherosclerosis is more fre-
quently observed in the elderly [36] and young women are 
normally considered a group free from atherosclerosis, in 
part because of the protective effects of estrogen [22, 37].  
  The high incidence of atherosclerosis in young women 
with SLE was initially noted in autopsy studies by Bulkley 
and Roberts [38] in 1975 where significant extent of athero-
sclerosis was observed in more than 50% of deceased pa-
tients independently of the cause of death. This finding was 
emphasized in a report on myocardial infarction and sudden 
death in 1976 where Urowitz et al. [39] described a bimodal 
distribution of the causes of death in SLE: An “early” peak 
caused by SLE severity/activity or infections, and a “late” 
peak caused by CVD. Not only does atherosclerosis occur 
more frequently in SLE patients than in the general popula-
tion, but there is also epidemiological and clinical evidence 
that it is accelerated in these patients [22, 40, 41].  
  The reason that premature coronary atherosclerosis de-
velops in patients with SLE is unknown. The leading theory 
is that immune complex deposition causes the initial intimal 
damage, which is followed by accelerated development of 
atherosclerosis in patients with traditional risk factors [42]. 
  Although the risk of CVD is raised in SLE, it is still not 
clear how atherosclerosis is related to this risk [43]. It should 
also be noted that SLE-related CVD and atherosclerosis may 
differ from other conditions such as diabetes and hyperten-
sion, where it is often assumed that these conditions confer 
an increased risk in general. It could be the case that CVD - 
like many other disease manifestations of SLE - only affects 
a subgroup of SLE patients [43]. Clearly, controlled, pro-
spective studies are needed to establish whether CVD is a 
general feature of the disease or more a complication affect-
ingonlyasubgroupofpatients [43]. Several studies suggested 
that atherosclerosis in SLE patients is characterized by an 
increased risk of localized plaque but not increased athero-
sclerosis in general, as determined by IMT measurements, at 
least not in patients with less severe disease [43-47]. 
CARDIOVASCULAR RISK FACTORS IN SLE 
  The prevalence of clinically manifest ischemic heart dis-
ease has ranged between 8% and 16% in various studies [48-
51]. The frequency of subclinical coronary artery disease 
(CAD) is likely to be considerably higher. Perfusion abnor-
malities have been reported in up to 38% of adult SLE pa-
tients [52-54] and in 16% of children [55]. Through the use 
of various noninvasive methods, atherosclerosis was detected 
in 28-40% of SLE patients [56-60], and was associated with 
increasing age and longer disease duration [61-65].  
  One important issue in SLE patients is to establish which 
are the risk factors for CVD and the role o traditional and 
non-traditional risk factors [43] (Table 1). Many SLE pa-
tients with renal disease or with a history of CVD are on 
treatment with blood pressure-lowering drugs, and in line 
with this, previous studies indicate that hypertension is an 
important risk factor for CVD in SLE [66]. In addition, 
smoking seems also to have an important role as traditional 
rosk factor in sle patients [67]. On the other hand treatment, 
especially the cumulative prednisone dose may also repre-
sent a non-traditional risk factor in these patients [68].  
  On important finding is to remember that in several stud-
ies, the Framingham risk factors did not fully account for 
CVD in SLE [69], therefore it is necessary to develop other 
methods to determine the subgroup of SLE patients that are 
at highest risk for CVD disease.  
Traditional Risk Factors 
  Only few studies have addressed the question of whether 
the frequency and level of traditional risk factors in SLE 
patients differ from those observed in age and sex-matched 
healthy controls [48, 69-72]. But there appear to be few sig-
nificant differences between patients and controls, although 
significantly higher concentrations of plasma homocysteine 
and triglycerides were reported in SLE patients [70-72]. 
Some studies concluded that CAD in SLE patients was not 
associated with recognized risk factors for CVD [74-76]. 
This conclusion needs to be regarded with some caution 
since some significant differences in the level and/or fre-
quency of these risk factors were detected in all studies com-
paring SLE patients with and without subclinical or clinical 
CAD [48].  
Table 1.  CAD Risk Factors in SLE 
Traditional risk factors  Immunological risk factors  Disease associated risk factors 
Hiperlipidaemia  Immune complex damage  Corticosteroid use 
Diabetes mellitus  Anntiphospholipid antibodies  Elevated homocystein levels 
Smoking  Pro-inflammatory cytocines  Renal disease 
Obesity   Hormonal 
Hypertension    
Family history of CAD     
Sedentary lifestyle     CVD in SLE  Current Cardiology Reviews, 2008, Vol. 4, No. 2    119
  Metabolic syndrome is considered an independent predic-
tor of cardiovascular morbidity and mortality that identifies 
substantial additional cardiovascular risk beyond the sum of 
the individual risk factors. In the general population, men 
with the metabolic syndrome were 1.9 - 3.0 times more 
likely to die of any cause, and 2.9 - 4.2 times more likely to 
die from coronary heart disease. Women with the metabolic 
syndrome also had a 2-fold increased risk of major adverse 
cardiovascular events and death. In addition to the cardio-
vascular risk factors that comprise the metabolic syndrome, 
there is a strong relationship with inflammation. In patients 
with lupus an increased prevalence of the metabolic syn-
drome, was observed, suggesting a common mechanism be-
tween premature atherosclerosis and inflammation, both fea-
tures of systemic lupus erythematosus [88]. 
  Nonetheless, it is clear that traditional risk factors do not 
fully account for the high risk of accelerated atherosclerosis 
among SLE patients and this suggests that disease-related 
factors constitute an equal or even greater risk. In another 
study the authors analyzed risk factors associated with the 
development of plaques and concluded that risk factors asso-
ciated with carotid plaque and IMT are those typically asso-
ciated with cardiovascular disease in the general population, 
whereas the risk factors associated with vascular stiffness 
include SLE-specific variables related to immune dysregula-
tion and complement metabolism [77]. Therefore two differ-
ent mechanisms may account for CAD in SLE patients and 
multicentric observational studies are needed to identify the 
role of each risk factor.  
Non Traditional Risk Factors 
  Several nontraditional risk factors may be found in SLE 
patients, including renal disease and corticosteroid use. An 
association between renal disease and the prevalence of risk 
factors for CAD was reported in several studies [78-80].  
  Among a large variety of disease- or treatment-related 
factors, only the duration or the cumulative dose of predni-
sone was consistently found to predict either atherosclerosis 
and subclinical or clinically overt CAD [81-85], but CAD 
may also develop in patients that never received corticoster-
oids [85]. Furthermore, nephritis and corticosteroid therapy 
are known to aggravate hyperlipidemia, hypertension and 
obesity [48].  
  Other disease-related factors are the inflammatory media-
tors released as a result of the chronic systemic inflammation 
associated with SLE, immune complex-mediated endothelial 
cell damage, and antiphospholipid antibodies [48]. Increased 
levels of anti-oxLDL have been found in SLE patients [86-
89], however the association with CVD is still unclear. The 
presence of antiphospholipid antibodies has been associated 
with angina and myocardial infarction [90-93]. Several stud-
ies have shown an association with increased carotid intima-
media thickness or plaque [94-96]. In SLE patients, data on 
the serum concentration of anti-HSP65 antibodies are het-
erogeneous and inconclusive [86, 97].  
  The results available to date are too inconsistent to allow 
any definite conclusions as to the role of inflammatory me-
diators in premature atherosclerosis. It has been proposed 
that SLE should be considered an independent cardiovascu-
lar risk factor. 
  Unfortunately, the conflicting nature of the data available 
to date does not allow any conclusions about the pathophysi-
ology of accelerated atherosclerosis in SLE patients or about 
possible preventive measures beyond the treatment of tradi-
tional risk factors. Prospective studies are necessary in order 
to address both of these issues [48]. 
MANAGEMENT 
  Although there are multiple risk factors for premature 
atherosclerosis in SLE and the individual importance of each 
factor has not been determined, SLE patients have to be 
treated. Preventive and symptomatic treatment should follow 
internationally guidelines, there is evidence that rheumatolo-
gists are not adequately implementing preventive strategies 
[10, 42]. Considering that SLE patients are young premono-
pausal women, and therefore should be considered s a high 
risk population for atherosclerosis and CVD [10]. 
  SLE patients who present with typical complaints should 
be worked up and managed as any other nonlupus patient 
[10]. Extra care should, however, be given to patients who 
present with nonspecific complaints such as chest discom-
fort, and/or dyspnea, and/or occasional palpitations [10].  
  Investigation with 99mTc-sestamibi myocardial perfu-
sion SPECT is a useful noninvasive imaging modality to 
detect cardiovascular involvement in SLE patients with non-
specific clinical complaints of heart disease. In fact, this 
technique was able to detect perfusion abnormalities in 27 of 
33 SLE patients with such complaints [98]. The presence of 
increased carotid IMT and the presence of discrete carotid 
plaque have been shown in many populations to correlate 
with prevalent atherosclerotic cardiovascular disease risk 
factors and with incident cardiovascular events, most com-
monly myocardial infarction [10, 99, 100]. 
  Aggressive treatment to reduce traditional risk factors 
should be encouraged in SLE patients, including treatment  
of : 1. hypertension (goal: BP <130/85 mmHg), 2. hypergly-
cemia, 3.smoking cessation, 4. weight management with 
ideal body weight under 25 kg/m2 and 4. maintain regular 
physical activity [10]. Furthermore hyperlipidemia should be 
aggressively treated with an ideal LDL around 100 mg/dl. 
Statins are particularly attractive in treating hyperlipidemia 
because of their additional independent impact on lowering 
levels of C-reactive protein, at least in patients, with docu-
mented coronary artery disease [10, 101]. The spectrum of 
direct antiatherogenic properties of statins includes mainte-
nance of endothelial function, anti-inflammatory actions, and 
a permissive action on smooth muscle cell proliferation that 
allows for synthesis of extracellular matrix proteins involved 
in the reparative response [10].Antimalarials may also be 
used because of its beneficial effects on lipid profile [102].  
CONCLUSIONS 
  Parallels between the inflammatory and immunemediated 
mechanisms of both atherogenesis and SLE may provide 
clues to understanding premature vascular disease in SLE 
patients. SLE-related factors are likely involved in all stages 120 Current Cardiology Reviews, 2008, Vol. 4, No. 2 Zeller and Appenzeller 
of atherogenesis from formation of the atherosclerotic lesion 
to its rupture, as well as in the thrombotic event itself. 
  SLE patients should be considered as high risk patients 
for CAD and modification of risk factors should be aggres-
sively persuade in SLE patients.  
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